Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection
A legfontosabb adatok
- Ki végzi
- TenNor Therapeutics (Suzhou) Limited
- Hol
- Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Befejeződött
- Fázis
- 3. fázis
- Résztvevők
- 700 fő vett részt
- Kezdés
- 2023. máj. 18.
- Befejezés
- 2024. márc. 26.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Rifasutenizol capsules
- Rabeprazole sodium enteric-coated tablets
- Amoxicillin Capsules
- Clarithromycin placebo tablets
- Bismuth potassium citrate placebo capsules
- Clarithromycin tablets
- Bismuth potassium citrate capsules
- Rifasutenizol placebo capsules
- A regiszteradat frissítve
- 2025. augusztus 17.
Ki vehet részt
- Életkor
- 18 év – 65 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 28 feltétel megnézéseKevesebb
Ki vehet részt
- Voluntarily sign the informed consent form
- Age 18-65 years (inclusive), male or female
- The result of 13C-UBT is positive (≥ 4 Delta Over Baseline), and the infection of H. pylori are confirmed by gastroscopic biopsy histology
- Subjects agree to refrain from taking any antibiotics or traditional Chinese medicines with antibacterial effect, bismuth, and antacids (such as proton pump inhibitor, H2 receptor blocker, P-CAB) other than the study drugs during the Screening Period until the end of the study (Visit 5, i.e., Efficacy Evaluation Visit)
- Subjects and their heterosexual partners must agree to have no pregnancy plan and voluntarily take effective contraceptive measures during the trial and for at least 6 months after the end of the study medication
- Willing to follow and able to complete all trial procedures
Ki nem vehet részt
- History of neoplasm malignant within 5 years prior to screening, with the exception of basal cell carcinoma or carcinoma cervix in situ treated without evidence of recurrence
- History of substance abuse or drug use within 5 years prior to screening
- Alcohol abuse or a history of alcohol abuse within 5 years prior to screening (average weekly consumption of ≥ 14 units of alcohol: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine/Chinese rice wine/rice wine)
- Anticoagulant therapy or long-term treatment with nonsteroidal anti-inflammatory drugs
- Treatment with any other investigational new drugs within 4 weeks prior to the Screening Period
- Any prohibited medications or non-drug therapies as specified in the protocol (see Section 10.3)
- History of H. pylori eradication therapy (including participation in other clinical trials for H. pylori eradication)
- Subjects with confirmed tuberculosis (TB) or Mycobacterium avium complex (MAC) infection or a history of TB or MAC infection
- History of dysphagia or any gastrointestinal disorder affecting drug absorption
- History of obstruction pyloric; or excessive gastric acid secretion (such as Zollinger-Ellison syndrome)
- History of gastric cancer
- History of esophageal or gastric surgery, except for simple repair of the perforated ulcer
- Presence of active gastric and/or duodenal ulcer
- Test positive for hepatitis B surface antigen, hepatitis C antibody, AIDS antibody, or microspironema pallidum antibody
- Other conditions considered inappropriate to participate in this study by the Investigator, e.g., the subject has a history of severe central nervous system, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urological, endocrine, or hematological diseases, or has clinical manifestations of these diseases
- Allergy to any of the study drugs (rabeprazole, amoxicillin, clarithromycin, bismuth potassium citrate), allergic constitution (multiple drug and food allergies); or any contraindication to the use of rifamycin, nitroimidazoles or study drugs
- White blood cell count or neutrophil count below the lower limit of normal range
- Anemia (hemoglobin < 90 g/L)
- Aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, or serum creatinine above the upper limit of normal range
- Abnormal ECG with clinical significance
- Female subjects who are pregnant, lactating, or have a positive urine pregnancy result during the Screening Period
- Inability to communicate with the Investigator and to comply with the study requirements
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
A multi-center, randomized, double-blind, bismuth-containing quadruple active comparator-controlled Phase 3 clinical study to evaluate the efficacy and safety of Rifasutenizol in combination with rabeprazole and amoxicillin in the primary treatment of participants with H. pylori infection using an adaptive design with sample size re-estimation.
A vizsgálat 2 csoportja
- Test GroupA vizsgált kezelés
Rifasutenizol capsules 400 mg + Rabeprazole sodium enteric-coated tablets 20 mg + Amoxicillin capsules 1 g + Bismuth potassium citrate placebo capsules + Clarithromycin placebo tablets, twice daily (BID) for 14 days
Kezelés: Rifasutenizol capsules, Rabeprazole sodium enteric-coated tablets, Amoxicillin Capsules, Clarithromycin placebo tablets és Bismuth potassium citrate placebo capsules
- Control GroupMár használt kezelés, összehasonlításként
Amoxicillin capsules 1 g + Clarithromycin tablets 500 mg + Rabeprazole sodium enteric-coated tablets 20 mg + Bismuth potassium citrate capsules 240 mg + Rifasutenizol placebo capsules, BID for 14 days
Kezelés: Rabeprazole sodium enteric-coated tablets, Amoxicillin Capsules, Clarithromycin tablets, Bismuth potassium citrate capsules és Rifasutenizol placebo capsules
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Rifasutenizol (TNP 2198) in Combination With Rabeprazole and Amoxicillin in the Primary Treatment of Participants With H. Pylori Infection
- Publikációk
- Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial.The Lancet. Infectious diseases, 2026
- A regiszteradat frissítve
- 2025. augusztus 17.